Literature DB >> 26297301

Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.

Joseph Cannova1, Peter Breslin S J, Jiwang Zhang.   

Abstract

Toll-like receptors (TLRs), which are found in innate immune cells, are essential mediators of rapid inflammatory responses and appropriate T-cell activation in response to infection and tissue damage. Accumulating evidence suggests that TLR signaling is involved in normal hematopoiesis and specific hematologic pathologies. Particular TLRs and their downstream signaling mediators are expressed not only in terminally differentiated innate immune cells but also in early hematopoietic progenitors. Sterile activation of TLR signaling is required to generate early embryonic hematopoietic progenitor cells. In adult animals, TLR signaling directly or indirectly promotes differentiation of myeloid cells at the expense of that of lymphoid cells and the self-renewal of hematopoietic stem cells during infection and tissue damage. Activating mutations of the MyD88 gene, which codes for a key adaptor involved in TLR signaling, are commonly detected in B-cell lymphomas and other B-cell hematopathologies. Dysregulated TLR signaling contributes to the pathogenesis of many hematopoietic disorders, including bone marrow failure, myelodysplastic syndrome, and acute myeloid leukemia. Complete elucidation of the molecular mechanisms by which TLR signaling mediates the regulation of both normal and pathogenic hematopoiesis will prove valuable to the development of targeted therapies and strategies for improved treatment of hematopoietic disorders.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26297301     DOI: 10.1007/s11684-015-0412-0

Source DB:  PubMed          Journal:  Front Med        ISSN: 2095-0217            Impact factor:   4.592


  163 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues.

Authors:  Steffen Massberg; Patrick Schaerli; Irina Knezevic-Maramica; Maria Köllnberger; Noah Tubo; E Ashley Moseman; Ines V Huff; Tobias Junt; Amy J Wagers; Irina B Mazo; Ulrich H von Andrian
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

3.  The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate.

Authors:  K De Luca; V Frances-Duvert; M-J Asensio; R Ihsani; E Debien; M Taillardet; E Verhoeyen; C Bella; S Lantheaume; L Genestier; T Defrance
Journal:  Leukemia       Date:  2009-07-30       Impact factor: 11.528

4.  Proinflammatory signaling regulates hematopoietic stem cell emergence.

Authors:  Raquel Espín-Palazón; David L Stachura; Clyde A Campbell; Diana García-Moreno; Natasha Del Cid; Albert D Kim; Sergio Candel; José Meseguer; Victoriano Mulero; David Traver
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

Review 5.  Pathophysiologic mechanisms in acquired aplastic anemia.

Authors:  Neal S Young
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

6.  TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta.

Authors:  Jonathan C Kagan; Tian Su; Tiffany Horng; Amy Chow; Shizuo Akira; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2008-02-24       Impact factor: 25.606

7.  Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.

Authors:  Ganesan Keerthivasan; Yang Mei; Baobing Zhao; Ling Zhang; Chad E Harris; Juehua Gao; Ashley A Basiorka; Matthew J Schipma; James McElherne; Jing Yang; Amit K Verma; Andrea Pellagatti; Jacqueline Boultwood; Alan F List; David A Williams; Peng Ji
Journal:  Blood       Date:  2014-06-02       Impact factor: 22.113

8.  Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta.

Authors:  Zhengfan Jiang; Tak W Mak; Ganes Sen; Xiaoxia Li
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

9.  Mutational and expressional analyses of MYD88 gene in common solid cancers.

Authors:  Eun Mi Je; Sung Soo Kim; Nam Jin Yoo; Sug Hyung Lee
Journal:  Tumori       Date:  2012 Sep-Oct

10.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

View more
  12 in total

1.  Constitutive Activation of NIK Impairs the Self-Renewal of Hematopoietic Stem/Progenitor Cells and Induces Bone Marrow Failure.

Authors:  Yan Xiu; Wingel Y Xue; Allyn Lambertz; Mariah Leidinger; Katherine Gibson-Corley; Chen Zhao
Journal:  Stem Cells       Date:  2016-11-02       Impact factor: 6.277

2.  Toll-Like Receptors 2 and 4 Modulate Pulmonary Inflammation and Host Factors Mediated by Outer Membrane Vesicles Derived from Acinetobacter baumannii.

Authors:  Chad R Marion; Jaewook Lee; Lokesh Sharma; Kyong-Su Park; Changjin Lee; Wei Liu; Pei Liu; Jingjing Feng; Yong Song Gho; Charles S Dela Cruz
Journal:  Infect Immun       Date:  2019-08-21       Impact factor: 3.441

3.  Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

Authors:  Kavita M Dhodapkar; Madhav V Dhodapkar; Akhilesh Kaushal; Ajay K Nooka; Allison R Carr; Katherine E Pendleton; Benjamin G Barwick; Julia Manalo; Samuel S McCachren; Vikas A Gupta; Nisha S Joseph; Craig C Hofmeister; Jonathan L Kaufman; Leonard T Heffner; Stephen M Ansell; Lawrence H Boise; Sagar Lonial
Journal:  Blood Cancer Discov       Date:  2021-09-01

4.  Targeting Toll-Like Receptors for Cancer Therapy.

Authors:  Marc J Braunstein; John Kucharczyk; Sylvia Adams
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

Review 5.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

6.  The Expression of Toll-like receptors in eutopic and ectopic endometrium and its implication in the inflammatory pathogenesis of adenomyosis.

Authors:  Caixia Jiang; Chao Liu; Jing Guo; Li Chen; Ning Luo; Xiaoyan Qu; Weihong Yang; Qing Ren; Zhongping Cheng
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

Review 7.  Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications.

Authors:  Nicola Stefano Fracchiolla; Bruno Fattizzo; Agostino Cortelezzi
Journal:  Stem Cells Int       Date:  2017-08-21       Impact factor: 5.443

8.  Molecular regulation of high muscle mass in developing Blonde d'Aquitaine cattle foetuses.

Authors:  Isabelle Cassar-Malek; Céline Boby; Brigitte Picard; Antonio Reverter; Nicholas J Hudson
Journal:  Biol Open       Date:  2017-10-15       Impact factor: 2.422

9.  Network Pharmacology-Based Investigation of the System-Level Molecular Mechanisms of the Hematopoietic Activity of Samul-Tang, a Traditional Korean Herbal Formula.

Authors:  Ho-Sung Lee; In-Hee Lee; Sang-In Park; Dae-Yeon Lee
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-13       Impact factor: 2.629

Review 10.  Innate Immune Memory in Hematopoietic Stem/Progenitor Cells: Myeloid-Biased Differentiation and the Role of Interferon.

Authors:  Lili Chen; Keiko Ozato
Journal:  Front Immunol       Date:  2021-03-29       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.